IN.PACT™ AV Access Post-Approval Study (PAS002)

Active, not recruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

June 3, 2025

Study Completion Date

February 28, 2029

Conditions
Arteriovenous FistulaArteriovenous Fistula StenosisArteriovenous Fistula OcclusionFistula
Interventions
COMBINATION_PRODUCT

IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort

For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.

COMBINATION_PRODUCT

IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort

For treatment of stenosis in the AV circuit

Trial Locations (20)

10029

The Mount Sinai Hospital, New York

10305

Staten Island University Hospital, Staten Island

12084

Albany Medical College, Albany

17602

Lancaster General Hospital, Lancaster

20010

Medstar Washington Hospital, Washington D.C.

22903

University of Virginia Medical Center, Charlottesville

28374

FirstHealth of the Carolinas, Pinehurst

29118

MUSC Health Dialysis Access Institute, Orangeburg

29303

Spartanburg Regional Medical Center, Spartanburg

32504

Coastal Vascular and Interventional, Pensacola

34102

NCH Healthcare System, Naples

48109

University of Michigan Health System - University Hospital, Ann Arbor

52242

University of Iowa, Iowa City

53713

University of Wisconsin-Madison - Meriter Hospital, Madison

55905

Mayo Clinic, Rochester

90048

Cedars-Sinai Heart Institute, Los Angeles

94301

Stanford University Medical Center, Stanford

97239

Oregon Health & Science University Hospital, Portland

06519

Yale New Haven Hospital, New Haven

07666

Holy Name Medical Center, Teaneck

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Medtronic

INDUSTRY

NCT04543539 - IN.PACT™ AV Access Post-Approval Study (PAS002) | Biotech Hunter | Biotech Hunter